TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31950979

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Intravenous hydrocortisone (50 mg every 6 hours) alone
Number of subjects: 216
Study: 29134571

Group type: EXPERIMENTAL
Intervention: goal‐ and learner‐centered video (GLV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: traditional video (TV)
Number of subjects: 110

Group type: COMPARATOR
Intervention: written text (WT)
Number of subjects: 110
Study: 27832548

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution with sweetener (CHO)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Taste-matched placebo (PLA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 18
Study: 24374357

Group type: EXPERIMENTAL
Intervention: Phonophoresis (PP) with capsaicin treatment and exercises
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo PP with capsaicin and exercises
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exercises only
Number of subjects: 61
Study: 22428427

Group type: EXPERIMENTAL
Intervention: Negative monitoring (judging words as negative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive monitoring (judging words as positive)
Number of subjects: 0
Study: 20185612

Group type: EXPERIMENTAL
Intervention: Medical Assistant Coaching (MAC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Contact Control (NCC)
Number of subjects: 100
Study: 19020160

Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion above the fascia (group AF, n = 29)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bupivacaine infusion below the fascia (group BF, n = 31)
Number of subjects: 62
Study: 15897784

Group type: EXPERIMENTAL
Intervention: Carvedilol therapy (group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard therapy (group 2)
Number of subjects: 58
Study: 11821265

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10510147

Group type: EXPERIMENTAL
Intervention: ER1Tab
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ER2Tab
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ER3Caps
Number of subjects: 12

Group type: COMPARATOR
Intervention: LR
Number of subjects: 12
Study: 1280862

Group type: EXPERIMENTAL
Intervention: Heparin (5,000 IU i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Org 10172 (3,250 anti‐Xa units i.v.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6703348

Group type: EXPERIMENTAL
Intervention: Epidural morphine 2 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural morphine 7.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural morphine (all doses)
Number of subjects: 40
Study: 30624568

Group type: EXPERIMENTAL
Intervention: Dietary intake of phylloquinone (vitamin K-1)
Number of subjects: 28356

Group type: EXPERIMENTAL
Intervention: Dietary intake of menaquinones (vitamin K-2)
Number of subjects: 28356

Group type: EXPERIMENTAL
Intervention: Total dietary intake of vitamin K
Number of subjects: 28356
Study: 29939764

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) in high-complexity conditions
Number of subjects: 120

Group type: COMPARATOR
Intervention: No Clinical Decision Support (no CDS) in high-complexity conditions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low task complexity
Number of subjects: 120
Study: 24503279

Group type: EXPERIMENTAL
Intervention: Methylphenidate as add-on therapy to mirtazapine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo as add-on therapy to mirtazapine
Number of subjects: 88
Study: 21920461

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy control
Number of subjects: 0
Study: 19188136

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² day 1 followed by weekly 250 mg/m²) + paclitaxel (225 mg/m²)/carboplatin (AUC6) day 1 every 3 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m² day 1 followed by weekly 250 mg/m²) + paclitaxel (100 mg/m²) days 1, 8, and 15 every 3 weeks and carboplatin (AUC6) day 1 every 4 weeks
Number of subjects: 168
Study: 17205514

Group type: EXPERIMENTAL
Intervention: Self-sampling for hrHPV testing
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (extra recall for conventional cytology)
Number of subjects: 284
Study: 15970000

Group type: EXPERIMENTAL
Intervention: Luteal FSH suppression by physiological oestradiol doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luteal oestradiol administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Premenstrual GnRH antagonist administration
Number of subjects: 0
Study: 12532716

Group type: EXPERIMENTAL
Intervention: Concomitant radio-chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory and experimental investigations
Number of subjects: 0
Study: 9881328

Group type: EXPERIMENTAL
Intervention: 0.3 mg of conjugated equine estrogen (CEE) daily (group 1)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen (CEE) daily (group 2)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study: 7997385

Group type: EXPERIMENTAL
Intervention: Torsemide 10 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Torsemide 20 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Torsemide 5 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 3396459

Group type: EXPERIMENTAL
Intervention: Auxiliary prescription labels (study sticker)
Number of subjects: 559

Group type: COMPARATOR
Intervention: No auxiliary prescription labels (control group)
Number of subjects: 559
Study: 31758556

Group type: EXPERIMENTAL
Intervention: TAU + 7 weekly 90-minute sessions of AF-EMDR (N = 55)
Number of subjects: 109

Group type: COMPARATOR
Intervention: TAU-only (N = 54)
Number of subjects: 109
Study: 29567761

Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-1 receptor antagonist (IL-1Ra) 100 mg administered twice daily for 3 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study: 29293697

Group type: EXPERIMENTAL
Intervention: Vitamin D 200 IU/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D 600 IU/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 0
Study: 26198744

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (n = 70)
Number of subjects: 140
Study: 23927819

Group type: EXPERIMENTAL
Intervention: High‐intensity aerobic interval exercise (HIA)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Home‐based exercise (HB)
Number of subjects: 115
Study: 21923854

Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced therapy (mitt on the unaffected hand for 2 hours each day for 8 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intensive occupational therapy (8 weeks)
Number of subjects: 50
Study: 19144261

Group type: EXPERIMENTAL
Intervention: Olopatadine HCl nasal spray 0.6% (OLO)
Number of subjects: 110
Study: 16697452

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including classroom-based curricula, family newsletters, and changes in the school food environment.
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 3600

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3600
Study: 12846417

Group type: EXPERIMENTAL
Intervention: Immunohistochemical (IHC) ODC assay
Number of subjects: 433
Study: 10976548

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg patch)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 21
Study: 9002806

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 20
Study: 1404796

Group type: EXPERIMENTAL
Intervention: Magnesium chloride, 2 g intravenous infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative normomagnesemic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postoperative hypomagnesemic patients
Number of subjects: 100
Study: 4003371

Group type: EXPERIMENTAL
Intervention: Cefoxitin antibiotic prophylaxis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 31062728

Group type: EXPERIMENTAL
Intervention: Methylene Blue (MB)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Patent Blue Violet (PBV)
Number of subjects: 237
Study: 29598955

Group type: EXPERIMENTAL
Intervention: Weight gain during chemotherapy (≥ 5% increase)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Weight loss during chemotherapy (≥ 5% decrease)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Stable weight during chemotherapy
Number of subjects: 1080
Study: 26913399

Group type: EXPERIMENTAL
Intervention: CHOPE regimen combined with thalidomide
Number of subjects: 80

Group type: COMPARATOR
Intervention: CHOPE regimen alone
Number of subjects: 80
Study: 24667057

Group type: EXPERIMENTAL
Intervention: Otologic Compass (OC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fisch elevator (Control)
Number of subjects: 25
Study: 22104168

Group type: EXPERIMENTAL
Intervention: Therapeutic intervention focused on relieving muscle hypertonicity in the deep compartment of the lower leg and restoring balance of the toe flexors and extensors (n = 7)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (Control group, n = 6)
Number of subjects: 20
Study: 20551303

Group type: EXPERIMENTAL
Intervention: SNPs (rs12334903, rs1456310, rs980171)
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Cluster of nine SNPs in prostate cancer risk region 1
Number of subjects: 563
Study: 18630535

Group type: EXPERIMENTAL
Intervention: Multiple cupping at back-shu points (n = 142)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Acupuncture at acupoints (n = 49)
Number of subjects: 191
Study: 15921758

Group type: EXPERIMENTAL
Intervention: 0.59‐mg fluocinolone acetonide intravitreal implant
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 2.1‐mg fluocinolone acetonide intravitreal implant
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 12358873

Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (n = 29) with conjugated equine oestrogen (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 61
Study: 10415739

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose of doxycycline (SDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (placebo)
Number of subjects: 0
Study: 7489696

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 31
Study: 2105538

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 100 mg daily for 2 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 473929

Group type: EXPERIMENTAL
Intervention: Intraarticular administration of 125 mg/0.5 ml Arteparon (6 injections)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 125 mg/0.5 ml Arteparon (10 injections)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intraarticular and Intramuscular administration of Arteparon
Number of subjects: 100
Study: 31429381

Group type: EXPERIMENTAL
Intervention: Traditional IPC (15-min preceding the trial)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPC x 2 (24-h and 15-min preceding)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: IPC x 3 (48-h, 24-h, and 15-min preceding)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control average (CONavg)
Number of subjects: 12
Study: 31465446

Group type: EXPERIMENTAL
Intervention: Public observation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Private observation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-social control
Number of subjects: 120
Study: 28031173

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1400 mg)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 743
Study: 25037651

Group type: EXPERIMENTAL
Intervention: Wheelchair‐bound Senior Elastic Band exercise program (40 minutes, three times per week for six months)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 114
Study: 23419328

Group type: EXPERIMENTAL
Intervention: TENS (n = 22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo-TENS (n = 20)
Number of subjects: 42
Study: 21042188

Group type: EXPERIMENTAL
Intervention: Furlow double‐opposing Z‐palatoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: von Langenbeck procedure
Number of subjects: 0
Study: 19512978

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16889680

Group type: EXPERIMENTAL
Intervention: OPCAB (off-pump coronary artery bypass grafting)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CABG (on-pump coronary artery bypass grafting)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 15264976

Group type: EXPERIMENTAL
Intervention: Self-help materials plus video
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Self-help materials, video, and telephone counseling
Number of subjects: 402
Study: 11527567

Group type: EXPERIMENTAL
Intervention: Saline iontophoresis at a current density of 0.2 mA/cm(2) for 4 hours
Number of subjects: 30
Study: 9269212

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 8511923

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with PMUE therapy: cisplatin (CDDP) 75 mg/m2, mitomycin C (MMC) 10 mg/body, etoposide 150 mg/body, and UFT 400 mg/day.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (surgery first, then PMUE therapy).
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) group.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Resection cases in NAC group.
Number of subjects: 55
Study: 3325230

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan-peptide complex ('Rumalon')
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30402206

Group type: EXPERIMENTAL
Intervention: High vegetable consumption (4200 g of vegetables/week)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low vegetable consumption (800 g of vegetables/week)
Number of subjects: 38
Study: 27026012

Group type: EXPERIMENTAL
Intervention: IoC1 and IoC2 monitoring
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 120
Study: 24819044

Group type: EXPERIMENTAL
Intervention: Consensus meeting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjustment of the regulatory instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing the number of inspectors per regulatory visit
Number of subjects: 0
Study: 22875224

Group type: EXPERIMENTAL
Intervention: Advanced Wound Care (AWC) dressings
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vacuum‐assisted closure (VAC) therapy
Number of subjects: 62
Study: 21081024

Group type: EXPERIMENTAL
Intervention: Rotational conjunctival flap (RCF) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple conjunctival closure (SCC)
Number of subjects: 0
Study: 18682346

Group type: EXPERIMENTAL
Intervention: Interactive small-group social norms correction
Number of subjects: 502

Group type: COMPARATOR
Intervention: Noninteractive social norms education
Number of subjects: 502
Study: 15883427

Group type: EXPERIMENTAL
Intervention: Low dietary zinc intake (3.8 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Supplemented zinc intake (18.7 mg/d)
Number of subjects: 14
Study: 12452732

Group type: EXPERIMENTAL
Intervention: Liposomal formulation of anthracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracycline-derivatives with lower toxicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardioprotective agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of anthracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timed sequential therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New diagnostic methods for minimal residual disease
Number of subjects: 0
Study: 10511019

Group type: EXPERIMENTAL
Intervention: Small capsulorhexis (4.5 to 5 mm)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Large capsulorhexis (6 to 7 mm)
Number of subjects: 75
Study: 7740949

Group type: EXPERIMENTAL
Intervention: Oral cefadroxil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Parenteral cefuroxime
Number of subjects: 52
Study: 1889702

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Sclerotherapy (among those who bled)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control (among those who bled)
Number of subjects: 106
Study: 7069203

Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: UVA treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: 8‐methoxypsoralen treatment
Number of subjects: 3
Study: 31151450

Group type: EXPERIMENTAL
Intervention: PBL plus high fidelity simulation training
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (90-min tutor-guided CPR hands-on training)
Number of subjects: 112
Study: 27834589

Group type: EXPERIMENTAL
Intervention: Crushed-ice pack applied to the shoulder for 15 min
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group applied a sandbag at skin temperature for 15 min
Number of subjects: 48
Study: 25260059

Group type: EXPERIMENTAL
Intervention: Dynamic fixation (TightRope; Arthrex)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Static fixation (3.5‐mm metallic screw)
Number of subjects: 70
Study: 24332521

Group type: EXPERIMENTAL
Intervention: Blue-violet LED irradiation after tooth extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blue-violet LED irradiation combined with hemostatic gelatin sponge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemostatic gelatin sponge only
Number of subjects: 0
Study: 22536131

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-γ) 50 μg/m² subcutaneously three times per week (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical betamethasone valerate 0.1% cream every night for 30 days (n = 20)
Number of subjects: 40
Study: 19696126

Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council scale
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Self-administered computerized versions of the baseline dyspnea index
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Transition dyspnea indexes
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: University of San Diego Shortness of Breath Questionnaire
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dyspnea ratings
Number of subjects: 101
Study: 17521397

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d (12 patients)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tablets (10 patients)
Number of subjects: 22
Study: 15203296

Group type: EXPERIMENTAL
Intervention: Fluoxetine or Paroxetine (active medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11380322

Group type: COMPARATOR
Intervention: LCM-7 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg twice daily for 7 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: LCMB-3 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, bismuth subcitrate 240 mg twice daily for 3 days)
Number of subjects: 118
Study: 9989329

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (non-participants)
Number of subjects: 0
Study: 8062489

Group type: EXPERIMENTAL
Intervention: Probenecid (2 gm) with adinazolam (60 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Adinazolam (60 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2839025

Group type: EXPERIMENTAL
Intervention: 1000 mg Calcium and 25 micrograms cholecalciferol per day
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 31524828

Group type: EXPERIMENTAL
Intervention: 13‐wk exercise program (n = 39)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual lifestyle control group (n = 31)
Number of subjects: 70
Study: 29310711

Group type: EXPERIMENTAL
Intervention: Collaborative pharmaceutical care with medication reconciliation and review performed by a clinical pharmacist during the experimental period
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control period with no clinical pharmacist
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Collaborative pharmaceutical care
Number of subjects: 630
Study: 25586058

Group type: EXPERIMENTAL
Intervention: Peginterferon (Peg‐IFN)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues (NUCs)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Baseline anti‐HBc level
Number of subjects: 791
Study: 24764070

Group type: EXPERIMENTAL
Intervention: High pressure and thermal dynamic sensitivity group
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Low pain sensitivity group
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: High thermal static sensitivity group
Number of subjects: 157